Dabur India Q4 PAT Rs 362 Crore Up 16 Percent Revenue at Rs 3038 Crore
- May 8, 2026
- Posted by: Neeraj Pandey
- Category: News
Dabur India Q4 results for FY26 announced on 7 May 2026 showed consolidated net profit rising 15.8% year on year to Rs 362 crore. The Dabur India Q4 revenue from operations grew 7.3% to Rs 3,038 crore, supported by continued demand across its health care, home and personal care, and food and beverages portfolio. The Dabur India Q4 performance reflects a recovering FMCG demand environment with rural markets gradually improving.
Investors tracking the Dabur India Q4 results FY26 will note that the board of directors recommended a final dividend of Rs 5.50 per equity share of face value Rs 1 for FY26, with the AGM scheduled for August 6, 2026. The Dabur India Q4 results build on a consistent track record of volume growth across its diversified portfolio of Ayurvedic and natural personal care products.
Get Free Stock Recommendations on Univest
Dabur India Q4 FY26 Results at a Glance
| Metric | Q4 FY26 / FY26 | Change |
|---|---|---|
| Q4 Revenue | Rs 3,038 crore | +7.3% YoY |
| Q4 Consolidated PAT | Rs 362 crore | +15.8% YoY |
| Q4 FY25 Revenue (comparison) | Rs 2,830 crore | Base period |
| Final Dividend | Rs 5.50 per share | FY26 payout |
| AGM Date | 6 August 2026 | Dividend subject to approval |
Track live financials and analyst ratings on the Univest Screener.
Key Highlights from Dabur India Q4 FY26
Health Care Portfolio Drives PAT Growth
The Dabur India Q4 results were underpinned by healthy growth across the health care portfolio including Chyawanprash, Honey, and Shilajit Gold, which benefited from heightened consumer focus on health and immunity products. The Dabur India Q4 healthcare segment demonstrated pricing power as the company was able to take selective price increases without significant volume impact.
Rural Recovery Supporting Volume Growth
The Dabur India Q4 revenue growth of 7.3% was supported by gradual rural demand recovery following the good monsoon of 2025. Rural-focused brands including Dabur Red Toothpaste, Odomos, and Dabur Janm Ghuti saw improved offtake. The Dabur India Q4 distribution reach of over 8 million retail outlets ensures broad market access as rural incomes improve.
International Business Contribution
Dabur’s international business, spanning the Middle East, Africa, South Asia, and North America, contributed positively to the Dabur India Q4 results. The international segment has been growing in double digits aided by the popularity of Dabur’s Ayurvedic products among the diaspora and health-conscious consumers globally.
Risks to Monitor
- Input cost inflation: Honey, herbal ingredients, and packaging cost increases can compress Dabur India Q4 gross margins if cost-led price increases are resisted by consumers.
- Rural demand uncertainty: Any reversal in rural income recovery or a below-normal monsoon would impact Dabur India Q4 rural volume growth trajectory.
- Competition in FMCG categories: Intensifying competition from HUL, P and G, and regional brands in personal care and food categories creates pricing pressure.
- Regulatory scrutiny on health claims: FSSAI and ASCI regulatory actions on health and wellness product claims could restrict marketing messaging for key Dabur India Q4 products.
Conclusion
The Dabur India Q4 results FY26 confirm a stable and predictable earnings outcome with PAT up 15.8% to Rs 362 crore and revenue up 7.3% to Rs 3,038 crore. The Dabur India Q4 dividend of Rs 5.50 per share reflects the company’s consistent capital return policy and confidence in its earnings trajectory.
For FY27, the most important variable for Dabur India Q4 investors is whether rural demand recovery sustains at 8 to 10% volume growth, and whether the international business can deliver double-digit growth to offset any near-term domestic volume moderation from input cost-led pricing increases.
Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.
Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Investments in the securities market are subject to market risk. Consult a SEBI-registered financial advisor before making any investment decisions.
Frequently Asked Questions
What was the Dabur India Q4 FY26 PAT?
Dabur India Q4 FY26 consolidated net profit was Rs 362 crore, up 15.8% year on year from Rs 320 crore in Q4 FY25, driven by healthcare portfolio growth and gradual rural demand recovery.
What is the Dabur India Q4 FY26 revenue?
Revenue from operations in the Dabur India Q4 results FY26 stood at Rs 3,038 crore, up 7.3% year on year from Rs 2,830 crore in Q4 FY25.
What dividend did Dabur India declare for FY26?
The Dabur India Q4 FY26 board recommended a final dividend of Rs 5.50 per equity share of face value Rs 1 for FY26. The AGM is scheduled for August 6, 2026, where shareholder approval will be sought.
What are Dabur India’s key brands?
Dabur India Q4 revenues come from brands including Dabur Chyawanprash, Dabur Honey, Real fruit juices, Dabur Red Toothpaste, Vatika, Odomos, Shilajit Gold, and Hajmola, spanning health care, personal care, and food segments.
What is Dabur India’s rural strategy?
The Dabur India Q4 rural strategy focuses on expanding its reach to 8 million plus retail outlets, launching affordable product pack sizes, and investing in rural-specific brands that resonate with value-conscious consumers.
Recent Article
Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026
